Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761683 | 0.92 | POLB (0.47) | TP53MAPTPOLBCYP19A1ALDH1A1 | |
| SCHEMBL5861449 | 0.88 | POLB (0.54) | TP53MAPTPOLBCYP19A1ALDH1A1 | |
| SCHEMBL5759940 | 0.87 | POLB (0.62) | TP53MAPTPOLBCYP19A1LMNA | |
| SCHEMBL5760368 | 0.87 | LMNA (0.50) | TP53MAPTPOLBCYP19A1ALDH1A1 | |
| SCHEMBL6022360 | 0.83 | POLB (0.53) | TP53MAPTPOLB | |
| SCHEMBL5760193 | 0.83 | POLB (0.46) | POLBCYP19A1 | |
| SCHEMBL5763003 | 0.82 | CYP19A1 (0.48) | TP53MAPTPOLBCYP19A1ALDH1A1 | |
| SCHEMBL5760654 | 0.82 | LMNA (0.48) | TP53MAPTPOLBGAALMNA | |
| SCHEMBL5761643 | 0.82 | AR (0.47) | MAPTPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL5761601 | 0.81 | MAPT (0.51) | TP53MAPTPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | claimed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | claimed |
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137228-A1 | Benzyl sulfonamide derivatives | AR, SHBG, BRDT | TP53 1975/4885MAPT 3579/4885POLB 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.